Abstract Objective To evaluate the efficacy of calf pulmonary surfactant (PS) in the treatment of respiratory distress syndrome (RDS) in late preterm and full-term infants. Methods A randomized controlled trial was designed to evaluate the efficacy of calf PS intratracheally given at different times and doses in infants with RDS who had a gestational age of ≥35 weeks and an oxygenation index (OI) of 10-20. The subjects were randomly assigned to treatment group 1 (n=58), treatment group 2 (n=58), and control group (n=59). Treatment group 1 was given PS (50 mg/kg) within 6 hours after admission. Treatment group 2 was given PS (70 mg/kg) within 6 hours after admission. The control group was not given PS within 6 hours after admission and was given PS (50 mg/kg) over 6 hours after admission if having no remission by conventional therapy including mechanical ventilation. For each group, a second dose of PS (50 mg/kg) was given if no remission was observed within 12 hours after the first administration. Results There were no significant differences in mortality between the three groups. Treatment group 2 had lower hospitalization expense and shorter duration of mechanical ventilation compared with treatment group 1, and treatment group 1 had lower hospitalization expense and shorter duration of mechanical ventilation compared with the control group. The incidence of ventilator-associated pneumonia and length of hospital stay in treatment group 2 was lower than those in treatment group 1 and control group. Compared with the control group, Treatment groups 1 and 2 showed decreases in 2 or more times of PS use, maximum OI, duration of continuous positive airway pressure treatment, and incidence of air leak syndrome and pulmonary hypertension. Conclusions Early use of sufficient PS in late preterm and full-term infants with RDS can reduce complications, secondary use of PS, duration of mechanical ventilation and length of hospital stay, and hospitalization expense.
ZHOU Wen-Li,ZHOU Qi,LI Cong et al. Early use of calf pulmonary surfactant in late preterm and full-term infants with respiratory distress syndrome：a randomized controlled trial[J]. CJCP, 2014, 16(3): 285-289.
ZHOU Wen-Li,ZHOU Qi,LI Cong et al. Early use of calf pulmonary surfactant in late preterm and full-term infants with respiratory distress syndrome：a randomized controlled trial[J]. CJCP, 2014, 16(3): 285-289.
Tita AT, Landon MB, Spong CY, et al. Timing of elective repeat cesarean delivery at term and neonatal outcomes[J]. N Engl J Med, 2009, 360(2): 111-120.
Ma X, Huang C, Lou S, et al. The clinical outcomes of late preterm infants: a multi-center survey of Zhejiang, China[J]. J Perinat Med, 2009, 37(6): 695-699.
[4]
Gouyon JB, Ribakovsky C, Ferdynus C, et al. Severe respiratory disorders in term neonates[J]. Paediatr Perinat Epidemiol, 2008, 22(1): 22-30.
[5]
Consortium on Safe Labor, Hibbard JU, Wilkins I, et al. Respiratory morbidity in late preterm births[J]. JAMA, 2010, 304(4): 419-425.
El Shahed AI, Dargaville P, Ohlsson A, et al. Surfactant for meconium aspiration syndrome in full term/near term infants[J]. Cochrane Database Syst Rev, 2007, 18: CD002054.
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants, 2010 update[J]. Neonatology, 2010, 97(4): 402-417.
[11]
Ghaemi S, Mohamadymasodi M, Kelishadi R. Evaluation of the effectes of surfactant replacement therapy in neonatal respiratory distress syndrome[J]. 中国当代儿科杂志, 2009, 11(3): 188-190.
